版本:
中国

BRIEF-Aurinia doses first patient in AURORA phase 3 clinical trial of voclosporin in lupus nephritis

May 17 Aurinia Pharmaceuticals Inc

* Aurinia doses first patient in AURORA phase 3 clinical trial of voclosporin in lupus nephritis

* Aurinia Pharmaceuticals - Trial to recruit 320 patients, intended to support full marketing approval of voclosporin for patients with LN Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐